Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Explicyte Immuno-Oncology I Cancer Immunotherapy CRO Services

At your side
to pioneer
immuno-oncology
therapies

favicon-white

We are a specialty contract research organization offering preclinical and translational research services for the development of novel anti-cancer immunotherapies.

Based in France, we have assisted international biotech and pharma companies, as well as comprehensive cancer centers for the past 10 years.

Our expertise in cancer immunotherapies

Cell-based Assays

Exploring anti-tumor immune response in sophisticated cellular models

In Vivo Models

Testing novel immunotherapies in well-characterized syngeneic tumor models

Translational Research

Discovering new targets and biomarkers in preclinical and clinical samples

NEWS

Explicyte Immuno-Oncology I Cancer ImmunoTherapy CRO Services

Explicyte immuno-oncology offers preclinical contract research services for cancer immunotherapy drug discovery and translational research services. Our preclinical CRO services range from cell-based assays – for the phenotypic screening of novel immunotherapeutics and the in vitro determination of the molecular mechanism of action of new anti-cancer immune modulators – to in vivo studies, using syngeneic mouse tumor models treated with antitumor immunotherapies such as immune checkpoint inhibitors (anti-CTLA-4 monoclonal antibodies, anti-PD1/PDL-1 antibody therapy). Furthermore, we offer to explore the in vivo mechanism of action of innovative immunotherapies such as anti-cancer vaccines, gut microbiota modulators, and CAR-T and NK cell therapies, through the profiling of the anti-tumor immune response by flow cytometry, quantitative digital pathology, and RT-qPCR. In addition, we provide translational services in immuno-oncology. Working with patient biopsies (liquid or solid samples), we can assist clinicians in the discovery of novel cancer targets and biomarkers of cancer immunotherapies. In the context of clinical trials, we offer biomarker testing and biomarker research services. Our flow cytometry team has a 10-year expertise in biomarker analysis in plasma, serum, and PBMC samples.  We also offer to analyze tumor biopsies using digital pathology, spatial transcriptomics, and Olink-based proteomics.  All our drug development services for cancer immunotherapy are performed in Bordeaux, France, serving clients all around the world, including sponsors in Europe (EU and outside), Germany, Belgium, Spain, UK, USA, Canada, Japan, and Korea.